AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
262.29B
Market cap262.29B
Price-Earnings ratio
25.26
Price-Earnings ratio25.26
Dividend yield
1.86%
Dividend yield1.86%
Average volume
2.68M
Average volume2.68M
High today
$172.05
High today$172.05
Low today
$171.70
Low today$171.70
Open price
$169.86
Open price$169.86
Volume
33.10K
Volume33.10K
52 Week high
$212.71
52 Week high$212.71
52 Week low
$142.98
52 Week low$142.98

Stock Snapshot

The current AstraZeneca(AZN) stock price is $171.70, with a market capitalization of 262.29B. The stock trades at a price-to-earnings (P/E) ratio of 25.26 and offers a dividend yield of 1.86%.

As of 2026-07-27, AstraZeneca(AZN) stock has fluctuated between $171.70 and $172.05. The current price stands at $171.70, placing the stock 0.0% above today's low and -0.2% off the high.

The AstraZeneca(AZN)'s current trading volume is 33.1K, compared to an average daily volume of 2.68M.

During the past year, AstraZeneca(AZN) stock moved between $142.98 at its lowest and $212.71 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $142.98 at its lowest and $212.71 at its peak.

AZN News

TipRanks 39m
AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint

AstraZeneca (AZN) reports high-level results from the ALXN1210-TMA-313 Phase 3 clinical trial showed that Ultomiris did not achieve statistical significance for...

TipRanks 1h
AstraZeneca: Buy Rating Reiterated as Strong Q2, Robust Pipeline Support Unchanged 16,500 GBp Price Target

Analyst Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca and keeping the price target at p16,500.00. Unlock powerful investin...

TipRanks 2h
AstraZeneca raises interim dividend to $1.06 per share

06:03 EDT AstraZeneca (AZN) raises interim dividend to $1.06 per share Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...

Analyst ratings

80%

of 30 ratings
Buy
80%
Hold
13.3%
Sell
6.7%

More AZN News

Nasdaq 3h
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View

(RTTNews) - British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share...

AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
The Wall Street Journal 5h
AstraZeneca Posts Sales Growth on Oncology Strength

AstraZeneca reiterated its 2030 revenue target after a clinical trial failure earlier this month. Michael Nagle / Bloomberg News AstraZeneca AZN -0.14 %decreas...

AstraZeneca Posts Sales Growth on Oncology Strength
TipRanks 5h
AstraZeneca’s Alexion Reports Mixed Ultomiris Trial Results in HSCT‑TMA, Advances Paediatric Filings

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Simply Wall St 2d
AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value - simplywall.st

...

AstraZeneca Stock Leads 3 Cash Flow Picks Trading Below Fair Value - simplywall.st
TipRanks 3d
DB-Guide Trial: AstraZeneca and Daiichi Sankyo Expand ENHERTU’s First-Line Breast Cancer Strategy

AstraZeneca plc (GB:AZN), Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Pre...

TipRanks 3d
MIRANDA Trial Completion: AstraZeneca’s Tozorakimab Targets High-Risk COPD Market

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident...

TipRanks 3d
AstraZeneca Reports Q2 Earnings Next Week. What Investors Should Expect.

Drugs giant AstraZeneca (AZN) is set to report its Q2 earnings next week – July 27. Let’s look at what investors should expect. Unlock powerful investing tools...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.